Completed PHASE1 INTERVENTIONAL NCT00254449

Effect of NGX-4010 on ENFD and Sensory Function

A Randomized, Controlled, Open-Label Study to Investigate the Effect of NGX-4010 on Epidermal Nerve Fiber Density and Sensory Function in Healthy Volunteers

Sponsor: NeurogesX

Conditions Human Volunteers

Interventions NGX-4010

Updated 5 times since 2017 Last updated: Feb 12, 2009 Started: Nov 30, 2005 Completion: May 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Human Volunteers, this trial is completed. The trial is conducted by NeurogesX and has accumulated 5 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Nov 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

NeurogesX

Data source: NeurogesX

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Minneapolis, United States